Agostinetto, Elisa http://orcid.org/0000-0003-0295-7511
Gligorov, Joseph http://orcid.org/0000-0002-9900-6386
Piccart, Martine http://orcid.org/0000-0001-9068-8504
Article History
Accepted: 26 August 2022
First Online: 17 October 2022
Competing interests
: E.A. has received fees or honoraria for consultant roles for Eli Lilly and Sandoz and support for attending medical conferences from Eli Lilly, Genetic, Istituto Gentili, Novartis and Roche, all unrelated to the submitted work. J.G. has received fees or honoraria for consultant roles for Daiichi, Eisai, Exact Science, Gilead, Lilly, Merck, Novartis, Onxeo, Pfizer, Roche Genentech and Seattle Genetics, and works in an institution that receives research grants from Eisai, Exact Science and Roche Genentech, all unrelated to the submitted work. M.P. has received fees or honoraria for consultant roles for AstraZeneca, Camel-IDS/Precirix, Frame Therapeutics, Gilead, Immunomedics, Immutep, Lilly, Menarini, MSD, NBE Therapeutics, Novartis, Odonate, Pfizer, Roche Genentech, Seagen and Seattle Genetics, is part of the scientific board at Oncolytics, and works in an institution that receives research grants from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche Genentech, Servier and Synthon, all unrelated to the submitted work.
Free to read: This content has been made available to all.